Document:

Exhibit 10.3

 

Master Services Agreement Dated

Between Kitov Pharmaceuticals Limited
(Kitov)

and

Java Clincial Research Ltd ( JAVA) 

 

	
        CHANGE ORDER FORM (1)

         

	
        PROTOCOL NUMBER:

         
	K-302-03-01
	
        Kitov CONTACT:

         
	Mr Simcha Rock
	
        SUPPLIER CONTACT:

         
	Ms Ruth Nallen
	
        DATE OF REQUEST: 

         
	26 03 2014
	
        BRIEFLY DESCRIBE ORIGINAL ASSUMPTION AND NEW REQUEST:

         

        The Original MSA dated 04 February refers only to Java Professional
        and Pass through Fees.

        This change order reflects total agree PI Fees for both Republic
        of Ireland and Northern Ireland.

	ROI fees which will be paid in euro to Java Clinical Research
        ltd who will then pass it on to the PIs upon receipt of invoices.
	NI fees will be paid in sterling directly to the single Investigator
        site at Celerion.
	A detailed service agreement will be exchanged directly between
        Kitov Pharmaceuticals and Celerion.

 

	
        IMPACT (estimated effort and/or timeline):

         

        This change order has no impact on effort or timelines.

	
        COST:

        Total additional cost: €669,989.60

         

        Payment Terms:
        Payment details and schedules are detailed in Appendix 1 & 2

         

	Amendment:  This Change Order Form shall constitute a Contract Amendment to the MSA dated 04 February 2014 between Kitov and Java and shall apply only to the revision of PIs fees attached hereto.  In all other respects the terms and conditions of the MSA shall remain in full force and effect and shall be applied to this Contract Amendment.
	
        Kitov Pharmaceuticals Ltd

         

         

         

        /s/ Simcha Rock                             

        (Signature)

         

        26/3/2014                                         

        (Date)

         

         

         
	
        Java

         

         

         

        /s/ Ruth
        Nallen                               

        (Signature)

         

        26/03/2014                                  

        (Date)

 

 

Change order no 1 

Kitov/ Java MSA

        

 

Page 1 of 3

     

     

    

 

Appendix 1

 

PI Fees Republic
of Ireland 

Fees payable to Java Clinical Research
Ltd

 

 

	Study Reference K-03-01	 	 	 	 	 
	Estimate ROI  Investigator   Costs (Euro)	 	 	 	 	 
	Investigator fees	 	 	72,000.00	 	 	Cost per screen failure: €720 x 100 subjects
	 	 	 	257,500.00	 	 	Cost per randomised subject: €2575 x 100 subjects
	Total	 	 	329,500.00	 	 	 
	Other Investigator Pass through costs	 	 	 	 	 	 
	GP Patient Referral Fee	 	 	7,500.00	 	 	Estimate: 100 patients x €100 per patient
	Community Screening Clinics	 	 	7,500.00	 	 	Estimate: €1000 per site x 10 sites
	ABPM subject lifestyle inconvenience reimbursement	 	 	25,000.00	 	 	Screen failures: 100 x 1 x €50; Randomised subjects: 100 x 4 x €50
	Estimated receipted subject travel expenses	 	 	60,000.00	 	 	Screen failures:100 x 3 visits  x €50; Randomised subjects:100 x 9 visitsx €50
	Total	 	 	100,000.00	 	 	 
	Proposed  payment of PI fees	 	 		 	 	Estimate Invoice  Date 
	Upfront payment of  25%	 	 	82,375.00	 	 	Apr-14
	Payments every 2 months thereafter based on subject visits	 	 	 	 	 	 
	 	 	 	82,375.00	 	 	Jul-04
	 	 	 	82,375.00	 	 	Sep-14
	 	 	 	82,375.00	 	 	Nov-14
	 	 	 	329,500.00	 	 	
	Pass through Fees	 	 	 	 	 	 
	Upfront 25%	 	 	25,000.00	 	 	Apr-14
	 Following SIV completion	 	 	25,000.00	 	 	Jun-14
	Payments every 2 months thereafter based on exepditure	 	 	25,000.00	 	 	Aug-14
	Payments every 2 months thereafter based on exepditure	 	 	25,000.00	 	 	Oct-14
	 	 	 	100,000.00	 	 	

 

 

 

Change order no 1 

Kitov/ Java MSA     

 

Page 2  of
3             

     

     

    

 

Appendix 2

 

PI
Fees Northern Ireland 

Paid
and contracted directly to Celerion 

 

	MSA Kitov/ Celerion	 	Euro	 	 	Sterling	 
	 	 	 	 	 	 	 	 	 
	Patient Management /PI Fees	 	€	217,166.40	 	 	£	180,972.00	 
	 	 	 	 	 	 	 	 	 
	Pass through costs	 	€	6,000.00	 	 	£	5,000.00	 
	 	 	 	 	 	 	 	 	 
	PK sampling	 	€	17,323.20	 	 	£	14,436.00	 
	 	 	 	 	 	 	 	 	 
	Total	 	€	240,489.60	 	 	£	200,408.00	 

 

 

Change order no 1 

Kitov/ Java MSA

 

Page 3  of
3

     

     

    

 

Master Services Agreement Dated

Between Kitov Pharmaceuticals Limited
(Kitov)

and

Java Clinical Research Ltd ( JAVA) 

 

	
        CHANGE ORDER FORM (2)

         

	
        PROTOCOL NUMBER:

         
	KIT-302-03-01
	
        Kitov CONTACT:

         
	Mr Simcha Rock
	
        SUPPLIER CONTACT:

         
	Ms Ruth Nallen
	
        DATE OF REQUEST: 

         
	22 09 2014
	
        BRIEFLY DESCRIBE ORIGINAL ASSUMPTION AND NEW REQUEST:

         

	Project timelines have extended as the study will now be conducted
        in the UK as opposed to the Republic of Ireland as stated in the original MSA. The movement of the study to the UK necessitated
        additional feasibility assessments which resulted in the selection of 4 additional UK sites and a central laboratory in the UK.
        Kitov Pharmaceuticals will contract directly with ACM laboratories so this service is now excluded from the MSA. Kitov will also
        manage PI fees directly with UK sites, so the PI fees itemised in CO 1 will no longer be applicable to this MSA.

 

	Multiple protocol amendments were issued to facilitate recruitment.
        This resulted in the submission of multiple substantial amendment to the UK REC and MHRA. It also resulted in modifications to
        the eCRF and data management plan. Additionally REC approval, by means of submission of a substantial amendment to the REC, was
        required for each of the additional UK sites.

 

         

	
        IMPACT (estimated effort and/or timeline):

         

	Project preparation timelines extended by 4 weeks
	Study conduct time has extended by 20 weeks
	Milestone payments have been restructured as detailed below
        in payment terms

 

         

	COST:

Total additional cost: 

 

€ 96,716.34 Professional Fees

€ 9,968 Pass through Fees

 

Revised budget break down is included in Appendix 1.

Costs will be revisited if recruitment is completed earlier
than 27 March 2015 as detailed in the attached Appendix 1.

 

	GRAND  REVISED TOTAL  PROFESSIONAL FEES 	 	 	664,799.58	 
	less received to date	 	 	204,657.98	 
	 	 	 	 	 
	Balance 	 	 	460,141.60	 
	 	 	 	 	 
	20% following 10 subjects randomised	 	 	92,028.32	 
	10 % following 30  subjects randomised	 	 	46,014.16	 
	10 % following 50 subjects randomised	 	 	46,014.16	 
	10 % following 75 subjects randomised	 	 	46,014.16	 
	10 % following 100 subjects randomised	 	 	46,014.16	 
	10 % following 125 subjects randomised	 	 	46,014.16	 
	10 % following 150 subjects randomised	 	 	46,014.16	 
	10%  following LPLV	 	 	46,014.16	 
	5% following DB lock	 	 	23,007.08	 
	5% following final study Report	 	 	23,007.08	 
	 	 	 	460,141.60	 

 

	Amendment:  This Change Order Form shall constitute a Contract Amendment to the MSA dated 04 February 2014 and Change Order No 1 dated 26 March 2014 between Kitov and Java. In all respects the terms and conditions of the MSA shall remain in full force and effect and shall be applied to this Contract Amendment No 2
	
        Kitov Pharmaceuticals Ltd

         

         

         

        /s/ Simcha Rock                             

        (Signature)

         

        September
        23, 2014                       

        (Date)

         

         

         
	
        Java Clinical Research ltd 

         

         

         

        /s/                                                    

        (Signature)

         

        _________________________

        (Date)

 

Change order no 1 

Kitov/ Java MSA

     Page 1
                                         of 5

     

    

 

Appendix 1

Revised Professional
& Pass through fees

 

	Study Reference K-03-01	 	 	 	 	 
	 	 	 	 	 	 
	Projected Timelines:	 	 	 	 	 
	Project Preparation	14 weeks	18 weeks 	 	January 2014 – Mid-May
    2014
	Study Recruitment and Conduct Period	22 weeks	42 weeks	 	22 June 2014 - 27 March
    2015
	Close out period	12 weeks 	 	 	30 March 2015 - 19 June
    2015
	 	 	 	 	 	 
	Indication:	Hypertension 	 	 	 	 
	 	 	 	 	 	 
	Key Assumptions:	 	 	 	 	 
	Number of patients to be screened	300	 	 	 	 
	Number of patients to be randomised	150	 	 	 	 
	Sites	1 site NI 4 sites
    UK 	 	 	 
	Number of monitoring visits	Estimated pool of
    45 monitoring site visits	 
	Total CRF pages per patient	TBC	 	 	 	 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVITY	 	RATE	 	 	UNIT	 	EST. REQ.	 	 	ESTIMATED CHARGE	 	 	Comments
	 	 	€	 	 	 	 	Range	 	 	Range €	 	 	 
	Project Preparation	 	 	 	 	 	 	 	 	 	 	 	 	 
	PM project training	 	 	110.00	 	 	hour	 	 	16	 	 	 	1,760.00	 	 	To include protocol, CRF and SOP training
	CRA project training	 	 	85.00	 	 	hour	 	 	16	 	 	 	1,360.00	 	 	To include protocol, CRF and SOP training
	PM project preparation time	 	 	1,760.00	 	 	week	 	 	22	 	 	 	38,720.00	 	 	Includes site contacts/feasibility assessments to ensure all required systems are in place for study initiation, assistance with eCRF development to include advice on required CRF data fields, communication with Kitov Ltd on project related progress/issue
	PM Feasibility & Preparation UK sites	 	 	880.00	 	 	day	 	 	12	 	 	 	10,560.00	 	 	Site & laboratory feasibility and selection activities including  budget and contract negotiations
	CRA project preparation time	 	 	1,360.00	 	 	week	 	 	14	 	 	 	19,040.00	 	 	Includes site contacts/feasibility, communication with Kitov Ltd, collating all study related materials required for initiation, addressing site queries and issues, preparation/customisation of Investigator Study Files and Forms, collection of essential d
	CTA project preparation time	 	 	400.00	 	 	week	 	 	18	 	 	 	7,200.00	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Preparation total	 	 	 	 	 	 	 	 	 	 	 	 	78,640.00	 	 	 
	Regulatory and Ethics	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Review and submission of CTA to IMB (including submission of responses to any queries raised during review period)	 	 	3,840.00	 	 	submission	 	 	1	 	 	 	3,840.00	 	 	 
	Review and submission of CTA to MHRA (including submission of responses to any queries raised during review period)	 	 	3,840.00	 	 	submission	 	 	1	 	 	 	3,840.00	 	 	 
	Submission of  Substantial Amendment  to MHRA	 	 	120.00	 	 	hour	 	 	38	 	 	 	4,560.00	 	 	12 hours Amen1: 8 hours Ament 2 ;                                            16 hours Amen 3 :12 hours amendment 4
	Submission to National Ethics Committee in Northern Ireland  (including submission of responses to any queries raised during review period)	 	 	2,040.00	 	 	submission	 	 	1	 	 	 	2,040.00	 	 	 
	Submission to National Ethics Committee in Northern Ireland (including submission of responses to any queries	 	 	2,720.00	 	 	submission	 	 	1	 	 	 	2,720.00	 	 	 
	Preparation and submission of substantial amendments to National Ethics Committee in Northern Ireland	 	 	880.00	 	 	submission	 	 	7	 	 	 	6,160.00	 	 	 
	Management of R&D Office Approval, including budget negotiation	 	 	1,760.00	 	 	site	 	 	1	 	 	 	1,760.00	 	 	 

 

Change order no 1 

Kitov/ Java MSA

     Page
                                         2 of 5

     

    

 

	Regulatory total	 	 	 	 	 	 	 	 	 	 	 	 	24,920.00	 	 	Estimate  13 Belfast visits; 32 UK visits
	Clinical Operations	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Assuming 1 Belfast  Centre:  4  UK Regional Centres  -  estimated Monitoring Visit Pool of 45 visits ( 12 visits Belfast : 32UK)) 
	Site Qualification Visits	 	 	680.00	 	 	site	 	 	10	 	 	 	6,800.00	 	 	Site Visit preparation time for pre study visits  -  2 hours. Site Visit preparation time for SIV and close out visit - 4 hours.  Site Qualification and Pre study visit duration - 4 hours. SIV and close out visit duration - 8 hours. Monitoring Visits  pre
	Travel time	 	 	400.00	 	 	site	 	 	6	 	 	 	2,400.00	 	 	 
	Site Qualification Visits UK	 	 	680.00	 	 	site	 	 	4	 	 	 	2,720.00	 	 	 
	Travel time UK	 	 	600.00	 	 	site	 	 	4	 	 	 	2,400.00	 	 	 
	Pre-Study Visits	 	 	850.00	 	 	site	 	 	5	 	 	 	4,250.00	 	 	 
	Travel time Belfast	 	 	200.00	 	 	visit	 	 	1	 	 	 	200.00	 	 	 
	Travel time UK	 	 	600.00	 	 	visit	 	 	4	 	 	 	2,400.00	 	 	 
	Site Initiation Visits	 	 	1,360.00	 	 	site	 	 	5	 	 	 	6,800.00	 	 	 
	Travel time Belfast	 	 	200.00	 	 	visit	 	 	1	 	 	 	200.00	 	 	 
	travel time UK	 	 	600.00	 	 	visit	 	 	4	 	 	 	2,400.00	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Study Monitoring Visits	 	 	2,040.00	 	 	site	 	 	45	 	 	 	91,800.00	 	 	 
	Travel time Belfast	 	 	200.00	 	 	visit	 	 	13	 	 	 	2,600.00	 	 	 
	Travel time UK	 	 	600.00	 	 	visit	 	 	32	 	 	 	19,200.00	 	 	 
	Study Close-Out Visits	 	 	1,360.00	 	 	site	 	 	5	 	 	 	6,800.00	 	 	 
	Travel time Belfast	 	 	200.00	 	 	visit	 	 	1	 	 	 	200.00	 	 	 
	Travel time UK	 	 	600.00	 	 	visit	 	 	4	 	 	 	2,400.00	 	 	 
	CRA Site Management	 	 	340.00	 	 	week	 	 	18	 	 	 	6,120.00	 	 	June - Sept 2014
	CRA Site Management	 	 	850.00	 	 	week	 	 	24	 	 	 	20,400.00	 	 	Oct - March 2015
	CRA Site Management	 	 	850.00	 	 	week	 	 	12	 	 	 	10,200.00	 	 	Close out period
	Project Management	 	 	2,200.00	 	 	week	 	 	52	 	 	 	114,400.00	 	 	Internal management of CRAs including advice on recruitment strategies, site related issues, contingency measurement implementation etc; Communication with Kitov Ltd on project progress/study related issues; Management of Third Party Vendors; Management o
	CTA study conduct	 	 	320.00	 	 	week	 	 	52	 	 	 	16,640.00	 	 	Assistance with compilation of return of essential dcoument for TMF, CRA travel arrangements, collation of all pass through costs and study related invoices.

 

Change order no 1 

Kitov/ Java MSA

     Page3 of                                          5

     

    

 

	Clinical Operations	 	 	321,330.00	 	 	 
	Other Services	 	 	 	 	 	 
	Clinical Laboratory Services (Estimate)	 	 	 	 	 	 
	Central Laboratory set up  Fee	 	 	5,874.00	 	 	ACM laboratory contracted directly with Kitov
	Data Management and Statistics	 	 	 	 	 	 
	Biometrics Management	 	 	11,172.00	 	 	 
	Data Management	 	 	42,873.50	 	 	 
	Amendment 1-3	 	 	5,133.50	 	 	 
	Amendment 4	 	 	27,522.00	 	 	 
	eCRF management and hosting	 	 	64,189.25	 	 	 
	Statistics	 	 	37,225.75	 	 	 
	 	 	 	188,116.00	 	 	 
	 	 	 	 	 	 	 
	Pharmacovigilance	 	 	 	 	 	 
	Safety Database Maintenance	 	 	4,000.00	 	 	 
	PhV Specifications	 	 	2,910.00	 	 	 
	SAE Initial/Follow-up Report Processing	 	 	3,600.00	 	 	 
	Expedite SUSARs reporting	 	 	108.00	 	 	 
	Line Listing production	 	 	2,440.00	 	 	 
	Responsible Person - Eudravigilance	 	 	6712.5	 	 	 
	Pharmacovigilance Subtotal	 	 	19,770.50	 	 	 
	 	 	 	 	 	 	 
	Medical Writing	 	 	 	 	 	 
	Clinical Study Report	 	 	14,252.00	 	 	 
	 	 	 	 	 	 	 
	Other Services Subtotal	 	 	222,138.50	 	 	 
	8% overhead	 	 	17,771.08	 	 	 
	 Preparation Regulatory & Clinops Subtotals	 	 	424,890.00	 	 	 
	 	 	 	 	 	 	 
	GRAND TOTAL  PROFESSIONAL FEES	 	 	664,799.58	 	 	 

 

	 	 	 	 	 	 	 
	Other study conduct  costs	 	 	 	 	 	 
	IMB CTA	 	 	1,443.00	 	 	 
	MHRA CTA + amendments	 	 	5,000.00	 	 	 
	Ethics Committe Fees	 	 	3,500.00	 	 	 
	CRA Travel	 	 	28,200.00	 	 	Belfast  site: 1 sites x 4 visits x €300 = €1200 (SQV/PS/SIV/C0)
	 	 	 	 	 	 	Belfast site: 1 x 13 visits x €300 = 3900
	 	 	 	 	 	 	UK sites: 4 sites x 4 visits  €500 =€8000 (SQV/PS/SIV/C0)
	 	 	 	 	 	 	UK sites: 32 x €500 = €16000
	Courier Costs - as per receipted expenses	 	 	8,000.00	 	 	Estimate
	Stationary, Printing, Photocopying for TMF, Investigator Site Files and Ethics Applications ; other	 	 	10,000.00	 	 	 
	Management of PI fees	 	 	9,885.00	 	 	 
	Estimate other pass through costs	 	 	66,028.00	 	 	 

 

Change order no 1 

Kitov/ Java MSA

     Page
                                         4 of
                                         5

     

    

	 	 	 	 	 
	GRAND TOTAL  PROFESSIONAL FEES	 	 	664,799.58	 
	less received to date	 	 	204,657.98	 
	 	 	 	 	 
	Balance	 	 	460,141.60	 
	 	 	 	 	 
	20% following 10 subjects randomised	 	 	92,028.32	 
	10 % following 30  subjects randomised	 	 	46,014.16	 
	10 % following 50 subjects randomised	 	 	46,014.16	 
	10 % following 75 subjects randomised	 	 	46,014.16	 
	10 % following 100 subjects randomised	 	 	46,014.16	 
	10 % following 125 subjects randomised	 	 	46,014.16	 
	10 % following 150 subjects randomised	 	 	46,014.16	 
	10%  following LPLV	 	 	46,014.16	 
	5% following DB lock	 	 	23,007.08	 
	5% following final study Report	 	 	23,007.08	 
	 	 	 	460,141.60	 

 

Change order no 1 

Kitov/ Java MSA

     Page
                                                                                      5 of 5

     

    

 

Master Services Agreement Dated

2nd April 2015

 

Between Kitov Pharmaceuticals Limited
(Kitov)

and

Java Clinical Research Ltd ( JAVA) 

 

	
        CHANGE ORDER FORM (3)

         

	
        PROTOCOL NUMBER:

         
	KIT-302-03-01
	
        Kitov CONTACT:

         
	Mr Simcha Rock
	
        SUPPLIER CONTACT:

         
	Ms Ruth Nallen
	
        DATE OF REQUEST: 

         
	2nd April 2015

 

BRIEFLY DESCRIBE ORIGINAL ASSUMPTION AND NEW REQUEST:

 

		
	·      Project
timelines have been extended as follows: 8 additional weeks in the study conduct 8 weeks interim analysis 

 

		·	The
budget is now reflective of up to 30 additional patients.  

 

		·	The
Monitoring visit schedule has been restructured. The total monitoring visits have increased from 45 to 56; 40 of which are two
day visits and 16 are one day visits. 

		·	3
additional sites in the UK have been included; the budget reflects additional site feasibility assessments and initiation and
close out visits allocated to these new sites.

 

		·	Protocol
amendments were issued to facilitate recruitment. This resulted in the submission of multiple substantial amendment to the UK
REC and MHRA. It also resulted in modifications to the eCRF and data management plan. Additionally REC approval, by means of submission
of a substantial amendment to the REC, was required for each of the additional UK sites.

 

	
        IMPACT (estimated effort and/or timeline):

        As stated above

         

        

	COST:

Total additional cost: 

 

€116,238.18

 

Revised budget break down is included in Appendix 1.

 

    Page 1 of
                                                                                      5

     

    

 

	GRAND TOTAL  PROFESSIONAL FEES 	 	 	781,037.76	 
	Less received to date 	 	 	388,714.62	 
	Invoice due for payment 30 March 2015	 	 	46,014.16	 
	 	 	 	434,728.78	 
	Balance Due 	 	 	346,308.98	 
	Revised Payment schedule ( based on montly resources)	 	 	 	 
	30-Apr-15	 	 	76,957.50	 
	30-Jun-15	 	 	76,957.50	 
	30-Aug-15	 	 	76,957.50	 
	30-Oct-15	 	 	76,957.50	 
	30-Dec-15	 	 	38,478.98	 
	 	 	 	346,308.98	 
	 	 	 	 	 
	 	 	 	 	 

 

	Amendment:  This Change Order Form shall constitute a Contract Amendment to the MSA dated 04 February 2014, Change Order No 1 dated 26 March 2014 and Change Order 2 dated 22 September 2014 between Kitov and Java. In all respects the terms and conditions of the MSA shall remain in full force and effect and shall be applied to this Change Order  No 3.
	
        Kitov Pharmaceuticals Ltd

         

         

         

        /s/ Simcha Rock                             

        (Signature)

         

        April 2,
        2015                                    

        (Date)

         

         

         
	
        Java Clinical Research ltd 

         

         

         

        /s/ Ruth
        Nallen                      

        (Signature)

         

        02 April
        2015                          

        (Date)

	 	 

 

Change order no 1 

Kitov/ Java MSA

 

    Page 2 of
                                                                                      5

     

    

 

Appendix 1

Revised Professional
fees

 

	Study Reference K-03-01	 	 	 	 	 
	 	Agreed V8 	Revised V9	 	 	 
	Projected Timelines:	 	 	 	 	 
	Project Preparation	18 weeks	 	 	January 2014 – Mid-May 2014
	Study Recruitment and Conduct Period	42 weeks	50 weeks	 	22 June 2014 - 05 June  2015
	Interim Analysis Recruitment and Conduct Period	 	8	 	08 June - 03 AUG
	Close out period	12 weeks 	12 weeks	 	03 AUG - 2 Nov	 
	 	 	 	 	 	 
	Indication:	Hypertension 	 	 	 	 
	 	 	 	 	 	 
	Key Assumptions:	 	 	 	 	 
	Number of patients to be screened	300	400	 	 	 
	Number of patients to be randomised 	150	150	 	 	 
	Number of patients randomised  during interim analysis	 	30	 	 	 
	Sites	5 sites	8 Sites	 	 	 
	Number of monitoring visits (180 patients)	Estimated pool of 56 monitoring site visits	 
	 	 	 
	Total CRF pages per patient	TBC	 	 	 	 

 

Change order no 1 

Kitov/ Java MSA

 

    Page 3 of
                                                                                      5

     

    

	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	ACTIVITY	 	RATE	 	 	UNIT	 	EST. REQ.	 	 	ESTIMATED CHARGE	 	 	Comments
	 	 	€	 	 	 	 	Range	 	 	Range €	 	 	 
	Project Preparation	 	 	 	 	 	 	 	 	 	 	 	 	 
	PM project training	 	 	110.00	 	 	hour	 	 	16	 	 	 	1,760.00	 	 	To include protocol,
    CRF and SOP training
	CRA project training	 	 	85.00	 	 	hour	 	 	16	 	 	 	1,360.00	 	 	To include protocol, CRF and
    SOP training
	PM project preparation time	 	 	1,760.00	 	 	week	 	 	22	 	 	 	38,720.00	 	 	Includes site contacts/feasibility
    assessments to ensure all required systems are in place for study initiation, assistance with eCRF development to include
    advice on required CRF data fields, communication with Kitov Ltd on project related progress/issue
	PM Feasibility & Preparation
    UK sites	 	 	880.00	 	 	day	 	 	12	 	 	 	10,560.00	 	 	Site & laboratory feasibility
    and selection activities including  budget and contract negotiations
	CRA project preparation time	 	 	1,360.00	 	 	week	 	 	14	 	 	 	19,040.00	 	 	Includes site contacts/feasibility,
    communication with Kitov Ltd, collating all study related materials required for initiation, addressing site queries and issues,
    preparation/customisation of Investigator Study Files and Forms, collection of essential d
	CRA project preparation
    time	 	 	2,040.00	 	 	site	 	 	3	 	 	 	6,120.00	 	 	additional 3 sites
	CTA project preparation time	 	 	400.00	 	 	week	 	 	18	 	 	 	7,200.00	 	 	 
	Preparation
    total	 	 	 	 	 	 	 	 	 	 	 	 	84,760.00	 	 	 
	Regulatory
    and Ethics	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Review and submission of CTA
    to IMB (including submission of responses to any queries raised during review period)	 	 	3,840.00	 	 	submission	 	 	1	 	 	 	3,840.00	 	 	 
	Review and submission of CTA
    to MHRA (including submission of responses to any queries raised during review period)	 	 	3,840.00	 	 	submission	 	 	1	 	 	 	3,840.00	 	 	 
	Submission of  Substantial
    Amendment  to MHRA	 	 	120.00	 	 	hour	 	 	38	 	 	 	4,560.00	 	 	12 hours Amen1: 8 hours Ament
    2 ; 16 hours Amen 3 :12 hours amendment 4
	Submission to National Ethics
    Committee in Northern Ireland  (including
    submission of responses to any queries raised during review period)	 	 	2,040.00	 	 	submission	 	 	1	 	 	 	2,040.00	 	 	 
	Submission to National Ethics
    Committee in Northern Ireland (including submission of responses to any queries	 	 	2,720.00	 	 	submission	 	 	1	 	 	 	2,720.00	 	 	 
	Preparation and
    submission of substantial amendments to National Ethics Committee in Northern Ireland	 	 	880.00	 	 	submission	 	 	12	 	 	 	10,560.00	 	 	 
	Preparation and
    submission of non substantial amendments to National Ethics Committee in Northern Ireland	 	 	220.00	 	 	submission	 	 	25	 	 	 	5,500.00	 	 	 
	Management of R&D Office
    Approval, including budget negotiation	 	 	1,760.00	 	 	site	 	 	1	 	 	 	1,760.00	 	 	 
	Submission fo R&D
    Office Amendment including revised budget negotiaition for QMUH	 	 	880.00	 	 	site	 	 	1	 	 	 	880.00	 	 	 
	Regulatory
    total	 	 	 	 	 	 	 	 	 	 	 	 	35,700.00	 	 	 
	Clinical
    Operations	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Site Qualification Visits	 	 	680.00	 	 	site	 	 	10	 	 	 	6,800.00	 	 	Site Visit preparation time
    for pre study visits  -  2 hours. Site Visit preparation time for SIV and close out visit - 4 hours. Site
    Qualification and Pre study visit duration - 4 hours. SIV and close out visit duration - 8 hours. Monitoring Visits  prep
	Travel time	 	 	400.00	 	 	site	 	 	6	 	 	 	2,400.00	 	 	 
	Site Qualification Visits UK	 	 	680.00	 	 	site	 	 	4	 	 	 	2,720.00	 	 	 
	Travel time UK	 	 	600.00	 	 	site	 	 	4	 	 	 	2,400.00	 	 	 
	Pre-Study Visits	 	 	850.00	 	 	site	 	 	8	 	 	 	6,800.00	 	 	 
	Travel time Belfast	 	 	200.00	 	 	visit	 	 	1	 	 	 	200.00	 	 	 
	Travel time UK	 	 	200.00	 	 	visit	 	 	4	 	 	 	800.00	 	 	 
	Site Initiation
    Visits	 	 	1,360.00	 	 	site	 	 	8	 	 	 	10,880.00	 	 	 
	Travel time Belfast	 	 	200.00	 	 	visit	 	 	1	 	 	 	200.00	 	 	 
	travel time UK	 	 	200.00	 	 	visit	 	 	7	 	 	 	1,400.00	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Study Monitoring
    Visits (2 day visits)	 	 	2,040.00	 	 	site	 	 	40	 	 	 	81,600.00	 	 	 
	Study Monitoring
    Visits (1 day visits)	 	 	1,360.00	 	 	site	 	 	16	 	 	 	21,760.00	 	 	 
	Travel time Belfast	 	 	200.00	 	 	visit	 	 	7	 	 	 	1,400.00	 	 	 
	Travel time UK	 	 	200.00	 	 	visit	 	 	49	 	 	 	9,800.00	 	 	 
	Study Close-Out
    Visits	 	 	1,360.00	 	 	site	 	 	8	 	 	 	10,880.00	 	 	 
	Travel time Belfast	 	 	200.00	 	 	visit	 	 	1	 	 	 	200.00	 	 	 
	Travel time UK	 	 	200.00	 	 	visit	 	 	7	 	 	 	1,400.00	 	 	 
	CRA Site Management	 	 	340.00	 	 	week	 	 	18	 	 	 	6,120.00	 	 	June - Sept 2014 (2 sites)
	CRA Site Management	 	 	510.00	 	 	week	 	 	12	 	 	 	6,120.00	 	 	Oct - Dec 2014 (5 sites)
	CRA Site Management	 	 	680.00	 	 	week	 	 	28	 	 	 	19,040.00	 	 	Jan - Aug 2015(8 sites) 1 hour
    per site per week
	CRA Site Management	 	 	1,360.00	 	 	week	 	 	12	 	 	 	16,320.00	 	 	Close out period  2
    hours per site per week
	Project Management	 	 	2,200.00	 	 	week	 	 	70	 	 	 	154,000.00	 	 	Internal management of CRAs
    including advice on recruitment strategies, site related issues, contingency measurement implementation etc.; Communication
    with Kitov Ltd on project progress/study related issues; Management of Third Party Vendors; Management
	CTA study conduct	 	 	320.00	 	 	week	 	 	70	 	 	 	22,400.00	 	 	Assistance with compilation of return of essential
    document for TMF, CRA travel arrangements, collation of all pass through costs and study related invoices.

 

Change order no 1 

Kitov/ Java MSA

    Page 4 of
                                                                                      5

     

    

 

	Clinical
    Operations	 	 	385,640.00	 	 	 
	Other Services	 	 	 	 	 	 
	Clinical
    Laboratory Services (Estimate)	 	 	 	 	 	 
	Central Laboratory set up  Fee	 	 	5,874.00	 	 	ACM laboratory contracted directly
    with Kitov
	Clinical Laboratory Services
    (Estimate) total	 	 	5,874.00	 	 	 
	 	 	 	 	 	 	 
	Data Management
    and Statistics	 	 	 	 	 	 
	Biometrics Management	 	 	15,361.00	 	 	 
	Data Management	 	 	52,313.50	 	 	 
	Statistics	 	 	37,225.75	 	 	 
	Amendment 1-3	 	 	5,133.50	 	 	 
	Amendment 4	 	 	27,522.00	 	 	 
	eCRF management and hosting	 	 	82,148.75	 	 	 
	Data Management
    and Statistics total	 	 	219,704.50	 	 	 
	 	 	 	 	 	 	 
	Pharmacovigilance	 	 	 	 	 	 
	Safety Database Maintenance	 	 	6,857.50	 	 	 
	PhV Specifications	 	 	2,910.00	 	 	 
	SAE Initial/Follow-up Report
    Processing	 	 	 	 	 	3600  only if  SAE
	Expedite SUSARs reporting	 	 	108.00	 	 	 
	Line Listing production	 	 	2,440.00	 	 	 
	Responsible Person - Eudravigilance	 	 	8,300.00	 	 	 
	Pharmacovigilance
    total	 	 	20,615.50	 	 	 
	 	 	 	 	 	 	 
	Medical Writing	 	 	 	 	 	 
	Clinical Study Report	 	 	14,252.00	 	 	 
	Medical Writing
    total	 	 	14,252.00	 	 	 
	Other Services
    Subtotal	 	 	 	 	 	 
	Summary	 	 	 	 	 	 
	Preparation total	 	 	84,760.00	 	 	 
	Regulatory total	 	 	35,700.00	 	 	 
	Clinical Operations total	 	 	385,640.00	 	 	 
	Other
    Services total	 	 	254,572.00	 	 	 
	8%
    overhead	 	 	20,365.76	 	 	 
	 	 	 	 	 	 	 
	GRAND
    TOTAL  PROFESSIONAL FEES	 	 	781,037.76	 	 	 

 

Change order no 1 

Kitov/ Java MSA

 

    Page 5 of
                                                                                      5EXHIBIT 10.4

 

 

SHARE TRANSFER AGREEMENT

 

THIS SHARE TRANSFER
AGREEMENT (this "Agreement") is made as of the 2nd day of April 2013 (the “Execution Date”),
by and among Mainrom Line Logistics Ltd., a public company traded on the Tel Aviv Stock Exchange (“Mainrom”),
Kitov Pharmaceuticals Ltd., a private company incorporated under the laws of the State of Israel (the "Kitov"),
and all the shareholders of Kitov, as detailed in Schedule A attached hereto (collectively referred to as the “Shareholders”),
the controlling shareholder of Mainrom, Sheer Roichman (“Roichman”) and Haiku Capital Ltd. (Israeli Co # 51-3783209)
(“Haiku”).

 

WITNESSETH:

 

WHEREAS, Roichman,
the controlling shareholder of Haiku, is the holder of 71.25% of Mainrom’s issued and outstanding shares;

 

WHEREAS, Mainrom
has no business activity and no liabilities, other than a liability to Roichman in the amount of up to NIS 300,000 representing
a loan given to Mainrom by Roichman (including any interest accrued thereon), and other liabilities as detailed in Schedule
‎5.1.5; and

 

WHEREAS, the
Shareholders desire to assign and transfer 10,000,000 ordinary shares, NIS 0.01 nominal value each, of Kitov (the “Transferred
Shares”), which represent 100% of the issued and outstanding share capital of Kitov on a fully diluted basis, to Mainrom
(the Transfer of the Transferred Shares shall be performed in two parts as more fully set forth in Section ‎1.1 below).

 

WHEREAS, in
consideration for the transfer of the Transferred Shares, Mainrom shall issue to the Shareholders ordinary voting shares of Mainrom
as follows: at the Closing Mainrom shall issue 17,569,220 ordinary shares of Mainrom representing 66.182% of Mainrom's issued share
capital on a fully diluted basis immediately following such issuance, taking into account all options granted under section ‎1.5
below (the "Closing Options") (the “Closing Issued Shares”); and in addition, subject
to Kitov's achievement of the Milestone (defined below), Mainrom shall issue to the Shareholders additional 17,927,776 ordinary
shares of Mainrom (the “Additional Shares”) which, together with the Closing Issued Shares and taking into account
the Closing Options, but disregarding any future issuance of securities and rights convertible into securities of Mainrom, represent
79.490% of Mainrom's issued share capital on a fully diluted basis, all as more fully set forth in Section‎1 below (together
the “Issued Shares”)(the “Share Exchange”); and

 

WHEREAS, Kitov,
the Shareholders, Roichman and Mainrom desire to effect and perform the Share Exchange pursuant to the terms and conditions more
fully set forth in this Agreement; and

 

NOW, THEREFORE,
in consideration of the mutual promises and covenants set forth herein, the parties hereby agree as follows:

 

    	 

    	 

    

  

		1	Transfer of the Transferred Shares and Issuance of the Issued Shares 

 

		1.1	At the Closing, Mainrom shall issue the Shareholders the Closing Issued Shares, and the Shareholders
shall transfer the Transferred Shares as follows: (a) 80% (or a lower percentage if required, as shall be determined by Mainrom,
in order to finalize the transaction) of the Transferred Shares held by each of the Shareholders (the "Closing Transferred
Shares") shall be transferred to Mainrom; and (b) 20% (or a higher percentage corresponding to the increase as set forth
in (a) above) of the Transferred Shares held by each of the Shareholders (the "Additional Holdings") shall be
transferred to a trustee which shall be mutually agreed following signing and if no such agreement is reached, as shall be determined
by Mainrom (the “Additional Holdings Trustee”) which shall hold such Additional Holdings in trust for
the sole benefit of Mainrom, pursuant to a trust agreement containing the language provided for in Schedule ‎1.1,
and transfer the Additional Holdings to Mainrom upon the earlier of: (i) the issuance of the Additional Shares to the Shareholders;
or (ii) at the lapse of a 28 months period commencing as of the date of the Closing (the "Trustee Transferred Shares").

 

		1.2	For avoidance of doubt, it is hereby clarified that each reference to Mainrom’s shares, under
each definition (including Closing Issued Shares, Issued Shares and Additional Shares) shall refer to Mainrom's Ordinary voting
Shares.

 

		1.3	Subject to Kitov's completion of a milestone set forth in Schedule ‎1.3 attached
hereto (the "Milestone") within 28 months from the date of the Closing, Mainrom shall, within 14 days as of the
completion of the Milestone, issue the Shareholders the Additional Shares.

 

		1.4	The number of Transferred Shares to be transferred by each Shareholder to Mainrom and the number
of Issued Shares to be issued by Mainrom to each Shareholder shall be as detailed in Schedule ‎1.4  attached
hereto.

 

			The Issued Shares shall have all the rights and privileges attached to the shares of Mainrom
                                                                             as set forth in Mainrom’s Articles of Association.

 

		1.5	Following the Closing, Mainrom shall (1) grant options to purchase 1,194,616 ordinary shares of
Mainrom under the terms and conditions set forth in Schedule ‎1.5B, to Lior Tamar Investments Ltd., or to any
third party (which shall receive a part of options under this section (1) all as shall be designated by Lior Tamar Investments
prior to April 22th 2013 and (2) grant Simcha Rock, subject to the adoption by the company of a stock option plan under
the provision of section 102 of the Israeli Income Tax Ordinance, an option to purchase 177,467 ordinary shares of Mainrom, and,
upon achievement of the Milestone and subject thereto, an option to purchase additional 181,089 ordinary shares of Mainrom, all
under the terms and conditions set forth in Schedule ‎1.5A.

 

    	2

    	 

    

  

		2	Closing and Delivery

 

		2.1	The closing of the Share Exchange under this Agreement (the “Closing”) shall
take place within five (5) days of the completion of the Closing Conditions (as defined below) at the offices of Shibolet &
Co. Advocates and Notaries in Tel Aviv, or at such other time or place as the Shareholders and Mainrom may mutually agree (such
date is hereinafter referred to as the “Closing Date”). In the event that the Closing Conditions are met, the
Share Exchange shall be deemed, for any and all purposes, to be effective as of the date of the Closing. In the event that all
the Closing Conditions are not met or waived by the applicable party on or prior to May 31 2013, this Agreement shall terminate
and shall be of no force and effect and none of the parties shall have any claims or demands against the other parties with respect
hereto, except in the event of a party that has not acted in good faith in order to achieve such Closing Conditions which were
not met.

 

		2.2	At the Closing, the transactions set out in Sections ‎2.3, ‎2.4, ‎2.5 and ‎3 below
shall occur, which transactions shall be deemed to take place simultaneously and automatically and no transaction shall be deemed
to have been completed or any document delivered until all such transactions have been completed and all required documents delivered:

 

		2.3	The Shareholders shall deliver to Mainrom the following documents:

 

		2.3.1	Original share transfer deeds duly signed and executed by each Shareholder transferring, the respective
number of Transferred Shares held by them to Mainrom.

 

		2.3.2	True and correct copies of a resolution of Kitov's board of directors approving the transfer of
the Transferred Shares to Mainrom, against issuance of the Issued Shares to the Shareholders.

 

		2.3.3	Any and all approvals and/or waivers and/or consents and/or permits or the like required for the
consummation of this Agreement executed by the Shareholders.

 

		2.3.4	A waiver, in the form attached hereto as Schedule ‎2.3.4, under which JPW PCH
LLC's right to purchase assets from Kitov is terminated.

 

		2.4	Mainrom shall deliver to the representative of the Shareholders the following documents:

 

		2.4.1	Shareholders Register reflecting the issuance of the Closing Issued Shares issued to the Nominee
Company (Hevra Le'rishumim). The shares will be issued to the Nominee Company for the benefit of a Trustee as shall be indicated
by the Shareholders and if not indicated (with a valid bank account) prior to the Closing, as shall be determined by Mainrom.

 

		2.4.2	A resolution of the board of directors of Mainrom issuing the Issued Shares to the Shareholders.

 

    	3

    	 

    

 

		2.4.3	A resolution of the meeting of the Shareholders of Mainrom approving the transaction hereunder.

 

		2.5	At the Closing, the Shareholders shall transfer to Mainrom the Closing Transferred Shares and shall
transfer to the Trustee the Trustee Transferred Shares and Mainrom shall issue each of the Shareholder the Closing Issued Shares
in accordance with the allocation among the Shareholders as detailed in Schedule ‎1.4 attached hereto.

 

		3	Board Composition.

 

All of Mainrom's currently residing
directors, excluding Issac Israel and the external directors, shall terminate their engagement as directors in Mainrom's
board of directors (the "Board"). At the Closing (or prior thereto) three (3) directors as detailed in Schedule ‎3A,
shall be appointed either by the Board or by the General Meeting of the Shareholders of Mainrom (the "General Meeting").
Attached hereto as Schedule ‎3B is a form of the declarations to be executed by such directors prior to the Execution
Date.

 

The Shareholders, together and
separately, hereby undertake and warrant to Roichman that until the completion of fund raising by Mainrom (either by way of a private
placement or a public offering) in the aggregate amount of at least NIS 15,000,000, they shall vote, at every General Meeting at
which the appointment of director(s) suggested by Roichman is on the Agenda of such General Meeting, for the appointment of a director
to the Board, the identify of whom shall be delivered in advance of such vote in writing by Roichman to the Shareholders (the "Director
Appointment Obligation"). Furthermore, the Shareholders, together and separately, hereby undertake that any
sale and/or transfer of Mainrom's securities held by such Shareholders after the Closing, other than a sale during trade on the
Tel Aviv Stock Exchange or the sale of all but not less than all of Mainrom’s outstanding share capital to a third party,
shall be subject to the obligation of the purchaser of such securities towards Roichman to abide by the Director Appointment Obligation
hereinabove.

 

		4	Transfer of the Transferred Shares.

 

Mainrom shall receive the Transferred
Shares on the basis of the representations and/or warranties to Mainrom with respect to the Transferred Shares and/or Kitov which
are set out in Section ‎7 below.

 

		5	Representations and Warranties of Mainrom and Haiku. 

 

		5.1	Mainrom hereby represent and warrant to the Shareholders and acknowledge that the Shareholders
are entering into this Agreement in reliance thereon, as follows:

 

		5.1.1	(i) this Agreement, when executed and delivered by Mainrom will constitute valid, binding and enforceable
obligations of Mainrom, and (ii) the Issued Shares transferred by Mainrom are free and clear of any liens, claims, encumbrances
or third party rights of any kind, including without limitation any rights of first refusal, co sale rights preemptive rights and/or
other participation rights and are, duly registered in the name of Mainrom in Mainrom’s share register.

 

    	4

    	 

    

  

		5.1.2	Mainrom's share capital on a pre-Closing, fully diluted basis, as filed with TASE, is attached
to this Agreement as Schedule ‎5.1.2 (“Mainrom's Capital”). Except as set forth in Mainrom'e
Capital, there are no outstanding nor promised options, warrants, securities convertible into, exchangeable or exercisable for
or evidencing the right to subscribe for equity securities of Mainrom, rights (including conversion, anti-dilution, exchange or
preemptive rights, rights of first refusal, share appreciation, profit sharing, phantom share rights, or any similar rights), proxy,
voting, transfer restriction or shareholder agreements, or agreements of any kind, or claims, undertakings or promises of any nature
whatsoever, orally or in writing, for the purchase, receipt or acquisition from Mainrom or from any other party, of any of its
securities. All issued and outstanding securities of Mainrom were issued in accordance with all applicable laws and regulations.

 

		5.1.3	Mainrom's public filings are and as of the Closing Shall be: (a) true and correct and accurately
represent Mainrom's business, its capital, assets and obligations; (b) be drafted (if applicable) according to IFRS and the Israeli
Securities Law, 1968 and the regulations promulgated thereunder and any applicable instruction and rules of the Israeli Securities
Authority; (c) do not include any misleading fact and do not as of the Closing, omit any material and/or extraordinary transaction
and/or action and/or event.

 

		5.1.4	On October 23rd, 2012 the Tel Aviv district court approvad the settlement by and among Mainrom
and its creditors under Section 350 of the Company's Law - 1999 (the "Settlement"). All publically available documents
of Mainrom published by it as of the Settlement and up to the Closing Date, are true and accurate in all material respects.

 

		5.1.5	The current financial obligations and other liabilities of Mainrom towards third parties and/or
towards Roichman are as set out in Schedule ‎5.1.5 attached hereto ("Mainrom's Financial Obligations").
Mainrom's Financial Obligations towards Roichman arise from actual funds directly advanced by Roichman to Mainrom and, for clarification
purposes, do not include in kind payments by Roichman. Following the Settlement, Mainrom has not conducted any activities other
than as strictly required to meet its reporting obligations to the TASE and, other than as disclosed hereunder,

 

		5.2	Haiku hereby represents and warrants to the Shareholders and acknowledges that the Shareholders
are entering into this Agreement in reliance thereon, as follows: (i) this Agreement, when executed and delivered by Haiku will
constitute valid, binding and enforceable obligations of Haiku; and (ii) Haiku is wholly owned by Roichman.

 

    	5

    	 

    

  

		6	Representations and Warranties of Roichman.

 

Roichman hereby represents and
warrants to the Shareholders and acknowledges that the Shareholders are entering into this Agreement in reliance thereon, as follows:
(i) Roichman has full power and authority to enter into this Agreement and this Agreement, when executed and delivered by Roichman
will constitute valid, binding and enforceable obligations of Roichman in accordance with its terms, except (a) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’
rights generally; and (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other
equitable remedies; (ii) no other action, consent, approval or authorization is necessary for the due authorization of the execution,
delivery and performance of this Agreement and the obligations of Roichman hereunder; and (iii) Roichman holds 5,418,886 ordinary
shares, with no nominal value, of Mainrom, constituting on a fully diluted basis taking into account all convertible securities
or rights thereto 71.25% of Mainrom's issued and outstanding share capital (the "Roichman Holdings"). The Roichman
Holdings are free and clear of any liens, claims, encumbrances, debt or third party rights of any kind, including without limitation
any other participation rights and are, duly registered in Roichman's name. To Roichman's best knowledge as the controlling shareholder
of Mainrom, following the Settlement, Mainrom has not conducted any activities other than as reported in its filings and as required
to meet its reporting obligations to the TASE and.

 

		7	Representations and Warranties of Kitov and the Shareholders. 

 

Kitov and each Shareholder, together
and separately, hereby represent, warrant and undertake, separately to Mainrom, Roichman and Haiku and acknowledge that each of
the above is entering into this Agreement in reliance thereon, as follows, as of the date of execution hereof and as of the Closing:

 

		7.1	(i) this Agreement, when executed and delivered by Kitov and each Shareholder will constitute valid,
binding and enforceable obligations of Kitov and such Shareholder; (ii) the execution, delivery and performance of the obligations
of Kitov and each Shareholder hereunder have been duly authorized by all necessary corporate action; (iii) the Transferred Shares
transferred by each Shareholders are free and clear of any liens, claims, encumbrances or third party rights of any kind, including
without limitation any rights of first refusal, co sale rights preemptive rights and/or other participation rights and are, duly
registered in the name of the Shareholders in Kitov's share register; and (iv) The current financial obligations and other liabilities
of Kitov towards third parties and/or towards the Shareholders of Kitov are as set out in Schedule ‎7.1‎0
attached hereto (the "Kitov Financial Obligations"). The Kitov Financial Obligations arise from actual
funds directly advanced by the Shareholders to the Company and, for clarification purposes, do not include in kind payments by
the Shareholders. Any other agreement and provision notwithstanding, no amount shall be repaid to the Shareholders until the full
repayment of all amounts due to Haiku and Roichman as set forth in Section ‎11 below, other than as set forth in Schedule 7.1
attached hereto, there are no obligations and other liabilities of Kitov towards its Shareholders.

 

    	6

    	 

    

  

		7.2	Immediately prior to the Execution Date and the Closing Date the authorized share capital of Kitov
is as set forth in Schedule A Except as set forth in Schedule ‎7.2, the Company has not and shall not issue and there are no
and there shall not, prior to the Closing Date, be any outstanding shares, options, warrants, preemptive rights or other rights
or securities, of any nature whatsoever, convertible into or exchangeable for shares of Kitov, or any other rights, agreements,
undertakings, promises or commitments to sell or acquire securities from Kitov. All issued and outstanding share capital of Kitov
was duly authorized, and is validly issued and outstanding and is fully paid for and non-assessable, and was issued in compliance
with all applicable laws concerning the issuance of securities.

 

		7.3	Kitov and the Shareholders hereby undertake that no later than April 10th, 2013 (the
"Delivery Date"), they shall deliver to Mainrom the following: (i) the draft of the Kitov description (Mit'ar)
(the "Mit'ar"); (ii) Kitov's Financial Statements as of December 31st, 2012 attached to the Mit'ar
(the "Financial Statements"); and (iii) Kitov's Valuation (the "Valuation" and together with
Mit'ar and Financial Statements the "Disclosure Documents").

 

		7.4	Kitov further undertakes, represents and warrants that as of the Delivery Date the Disclosure Documents
shall: (a) be true and correct and accurately represent Kitov's business, its capital, assets and obligations; (b) be drafted (if
applicable) according to IFRS and the Israeli Securities Law, 1968 and the regulations promulgated thereunder and any applicable
instruction and rules of the Israeli Securities Authority; (c) do not include any misleading fact and do not as of the Closing,
omit any material and/or extraordinary transaction and/or action and/or event; and (d) represent that as of December 31st,
2012 and until the Execution Date and the Closing, Kitov's business was and shall have been conducted in the ordinary course of
business.

 

		7.5	Should Kitov fail to deliver the Disclosure Documents until the lapse of the Delivery Date, Mainrom
shall be entitled, at its sole discretion, and in addition to and without derogating from any other legal remedy, to terminate
this Agreement and neither Kitov nor any of the Shareholders nor anyone on their behalf, shall have any claims and/or contents
of any kind or type against Mainrom, its shareholders, directors, officers, advisors, employees and/or successors with respect
to such termination.

 

		8	Conditions to Closing by Mainrom

 

The obligations of Mainrom to
receive the Transferred Shares and to issue the Issued Shares are subject to the fulfillment at or before the Closing of the following
conditions precedent, any one or more of which may be waived in whole or in part in writing by Mainrom, which waiver shall be at
the sole discretion of Mainrom (the “Mainrom Closing Conditions”):

 

		8.1	The representations and warranties made by Kitov and the Shareholders in Section 6 of this Agreement
shall have been true and correct when made and as of the Closing as if made on the date of the Closing;

 

		8.2	Mainrom's board of directors shall have duly approved the transactions contemplated hereunder,
including without limitation the issuance of the Issued Shares to the Shareholders.

 

    	7

    	 

    

  

		8.3	The meeting of the shareholders of Mainrom shall have duly approved: (i) the transactions contemplated
hereunder, including without limitation the issuance of the Issued Shares to the Shareholders; (ii) the increase of Mainrom's registered
share capital and (iii) the purchase of: (i) a directors and officers (D&O) insurance Policy; and (ii) a professional indemnity
insurance policy with an appropriate level of a "Run-off" cover for the benefit of its officers and directors which shall
not in any way derogate from the representations regarding Mainrom's Financial Obligations.

 

		8.4	Mainrom shall engage advisors, the identity of which shall be agreed between Mainrom and Kitov
prior to the Closing, for purposes of IR/PR services for a minimal period commencing as of the Closing as shall be agreed among
the parties.

 

		8.5	The Valuation, as shall be submitted to the Tel Aviv Stock Exchange Ltd. (the "Stock Exchange")
in accordance with the Stock Exchange rules and regulations, as in effect, for the purposes of determining the rate of Mainrom's
public holdings with respect to the Stock Exchange's requirements (the "Requirements"), shall reflect Kitov a
valuation of at least US$40,000,000.

 

		8.6	Mainrom shall have received the approval of the Stock Exchange for the issuance of the Issued Shares
and the shares underlying the Closing Options and the Conversion Option.

 

		8.7	All covenants, agreements, and conditions contained in this Agreement to be performed or complied
with by Kitov and/or the Shareholders, as applicable, prior to or at the Closing, shall have been performed or complied with by
Kitov and/or the Shareholders, as applicable, prior to or at the Closing.

 

		9	Conditions to Closing by the Shareholders

 

The obligations of the Shareholders
to transfer the Transferred Shares to Mainrom are subject to the fulfillment at or before the Closing of the following conditions
precedent (the “Shareholders Closing Conditions”; and together with Mainrom Closing Conditions, the “Closing
Conditions”) any one or more of which may be waived in whole or in part in writing by Shareholders holding the majority
of the shares of Kitov (the “Majority Shareholders”), which waiver shall be at the sole discretion of such Shareholders:

 

		9.1	The representations and warranties made by Mainrom and Haiku in Section ‎5 of this Agreement
shall have been true and correct when made and as of the Closing as if made on the date of the Closing;

 

		9.2	The meeting of the shareholders of Mainrom shall have duly approved: (i) the transactions contemplated
hereunder, including without limitation the issuance of the Issued Shares to the Shareholders; and (ii) the increase of the registered
share capital of Mainrom.

 

		9.3	Mainrom shall have no outstanding liabilities, other than the Mainrom Financial Obligations.

 

    	8

    	 

    

  

		9.4	In connection with and for purposes of meeting the Requirements, Roichman's Holdings shall not
exceed 3,800,000 ordinary shares of no nominal value of Mainrom in order for the public to hold at least 15% of the shares of Mainrom
and conform with applicable TASE requirements.

 

		9.5	A pre ruling from the Israeli Tax Authority in relation to the tax treatment of the Share Exchange
event between the Shareholders and Mainrom in accordance with Section 104B(f) and 103 of the Tax Ordinance (and not the personal
tax status of each Shareholder as a result thereof), shall have been received (the "Pre Ruling"). In the event
that the Pre Ruling is not received by April 22nd, 2013, and unless this Shareholders Closing Condition was previously waived by
the Majority Shareholders, Mainrom shall be entitled, at its sole discretion, and in addition to and without derogating from any
other legal remedy of Mainrom, to terminate this Agreement and neither Kitov nor any of the Shareholders nor anyone on their behalf,
shall have any claims and/or contents of any kind or type against Mainrom, its shareholders, directors, officers, advisors, employees
and/or successors with respect to such termination

 

		9.6	The approval by the Stock Exchange for the registration and trade of the Issued Shares,including
without limitation shares resulting from the exercise of Mainrom's exercisable securities if any;

 

		9.7	All covenants, agreements, and conditions contained in this Agreement to be performed or complied
with by Mainrom prior to or at the Closing, shall have been performed or complied with by Mainrom prior to or at the Closing;

 

		9.8	All of the documents to be delivered by Mainrom to the Shareholders shall have been delivered to
the Shareholders.

 

		9.9	All of Mainrom's currently residing directors, excluding Issac Israel and the external directors,
have terminated their engagement as directors in Mainrom's Board and Mainrom delivered a notice regarding their resignation to
the Company Registrar.

 

		10	Interim Period

 

		10.1	During the period commencing as of the Execution Date and ending upon the earlier of the Closing
Date or May 31 2013 (the "Interim Period"), Mainrom shall not perform, without the prior written approval of Kitov
, any action other than as (1) may be required by law or agreement which was in effect prior to the date hereof (2) or contemplated
hereunder or required for the consummation of the transaction contemplated hereunder or (3) in the ordinary course of operations
of Mairom as a publically traded company with no business activity.

 

		10.2	During the Interim Period, Kitov shall not perform, without the prior written approval of Mainrom,
any action other than as (1) may be required by law or agreement which was in effect prior to the date hereof (2) or contemplated
hereunder or required for the consummation of the transaction contemplated hereunder or (3) in the ordinary course of business
of Kitov.

 

    	9

    	 

    

  

		10.3	The above notwithstanding, During the Interim Period, neither Kitov nor any of the Shareholders
perform, without the prior written approval of Mainrom, any of the following: (a) dividend or bonus share distribution; or (b)
enter into negotiations, offering or soliciting third parties to acquire control of Kitov or its business activity (c) Issue or
sell or transfer any shares or securities of Kitov.

 

		10.4	Kitov shall provide Mainrom with any and all information and documents reasonably required by Mainrom
in connection with the Disclosure Documents and/or any other disclosure requirements under law or demand by the Securities Authority.

 

		10.5	The Parties acknowledge that certain Shareholders are entering into five (5) year Gain Recognition
Agreements (“GRAs”) with the Internal Revenue Service of the United States in order to avoid immediate taxation by
the United States as a result of the transactions contemplated in this Agreement.  Mainrom agrees that it will provide to
any Shareholder entering into a GRA all information reasonably requested by the Shareholder in writing, including notice (within
21 days of written request from any Shareholder) of the occurrence of any of the following events with respect to Mainrom or Kitov
during the tax period(s) specified by Shareholder: (a) any complete or partial disposition of any of the Transferred Shares or
any of the Kitov securities, whether such disposition occurs directly or indirectly by transfer of the majority of Mainrom securities;
(b) any disposition of substantially all of the assets of the Kitov; and (c) the entry of the Kitov into any partnership or joint
venture arrangements, whether directly or indirectly.

 

		10.6	Kitov and the Shareholders undertake that as of the Closing and immediately following the Closing
the Kitov Financial Obligations shall not exceed the following: (i) NIS1,000,000 with respect to financial obligations towards
third parties; and (ii) US$370,000 with respect to financial obligations towards the Shareholders.

 

		10.7	The Mainrom Financial Obligations towards Roichman as set forth in Section ‎5.1.5 above and
the Kitov Financial Obligations as set forth in Section ‎0 above shall be repaid to Roichman and the Shareholders simultaneously
and pro-rata to their respective debt amounts set forth above as of the Closing. It is hereby clarified that the repayment of the
above financial obligations shall be subject to and only following the payment in full of the Investments Consideration in Section
‎11.3 below.

 

		11	Haiku and/or Roichman Obligations and Benefits

 

		11.1	At the Closing, Haiku and/or Roichman (collectively the "Lender") shall advance
Mainrom a loan in the total amount of NIS 500,000 (the "Loan Amount"). The Loan Amount shall be repaid
to the Lender by Mainrom at such time in which Mainrom and/or Kitov shall raise as of the Closing (either by way of a private placement
or a public offering) an aggregate amount of at least NIS 500,000. Without derogating from any other legal rights and/or remedies
available to the Lender in connection therewith, if the Loan will not be repaid when due, Lender may, at its sole discretion, convert
the Loan Amount, into Mainrom's securities, at a conversion price reflecting a thirty (30) percent discount of the Applicable PPS
(as defined below) (the "Conversion Option").

 

    	10

    	 

    

  

For the purposes hereof, the
"Applicable PPS" shall mean the average price of Mainrom's ordinary Shares in the Stock Exchange during the 30
trading days period prior to the conversion notice by Lender. The above Conversion Option shall be subject to the approval of the
Stock Exchange and the approval of Mainrom's relevant organs, as legally required.

 

		11.2	In addition to the foregoing, in the event that Mainrom offers its shares to the public and in
such offer obtains preliminary obligations to purchase its securities under such public offering in an amount of at least NIS500,000,
then in such event the Lender hereby irrevocably and unconditionally commits to participate in such public offering by placing
orders to purchase the securities offered by Mainrom in such public offering in an amount of at least NIS750,000. Notwithstanding
the foregoing, in the event that public offering includes options to purchase Mainrom's shares in consideration for a "premium",
the Lender shall place orders to purchase the securities offered in such offering in an amount equal to NIS750,000 less the exercise
price of the offered options which will be purchased by him in the event that all of the Lender's order is fulfilled in whole.
For avoidance of doubt, in the event of such offering, the Loan Amount shall be repaid to the Lender immediately following such
offer. 

 

		11.3	Without derogating from the foregoing, Haiku shall be entitled to receive, out of all funds raised
by Mainrom, in a single or a series of transactions (in this Section the "Invested Amounts"), as follows: (i)
10% of all Invested Amounts up to an amount of NIS 9,000,000 in the aggregate; and (ii) 25% of all Invested Amounts exceeding NIS
9,000,000. Notwithstanding the foregoing the total cumulative amount to which Haiku shall be entitled under this Section ‎11.3shall
not exceed NIS 2,500,000 (the “Investments Consideration”). VAT shall be added to all amount set forth above
if applicable under any law.

 

		11.4	In the event that Mainrom's Financial Obligations at the Execution Date exceed the amounts listed
in Schedule ‎5.1.5 (the "Maximum Obligation"), i.e. that Mainrom's representation under Section ‎5.1.5
is found inaccurate, by more than NIS50,000, then Roichman shall indemnify the Shareholders, pro rata to their holdings in Mainrom
at the Closing, in an amount equal to 70% of the sum of the excess of Mainrom's Financial Obligations, provided however
that the indemnification amount shall not exceed NIS 1,000,000 (the "Indemnification Amount").

 

Roichman indemnification obligations
hereunder (the "Indemnification Obligation") shall be limited as follows: (i) the Indemnification Obligation shall
terminate upon the lapse of 18 month as of the Closing Date and to that extent the parties shall enter into a limitation agreement;
(ii) no claim for indemnification shall be brought unless the Indemnification Amount shall exceed NIS100,000 (in which case the
claim may be brought from the "first dollar"); and (iii) the Indemnification Obligation shall be limited to transfer
by Roichman of its Mainrom shares. Any other provision notwithstanding the Shareholders and/or Kitov and/or Mainrom shall not be
entitled to any monetary or other (except by Mainrom's shares as set forth in this sub-section (iii)) compensation from Roichman.
For the purpose of this section ‎11.4, the value of Roichman's shares shall be determined according to the average of (i) the
value of the shares in the transaction contemplated hereunder according to the Valuation, and (ii) the average value of the shares
during a period of 30 trading adding prior to the time of indemnification.

 

    	11

    	 

    

  

		12	Miscellaneous.

 

		12.1	Duration. This agreement shall be valid and binding for a period until the earlier of (a)
the Closing of the Share Exchange, or (b) three (3) months commencing as of the date hereof. Thereafter, in the event that the
Share Exchange has not occurred prior thereto, this Agreement shall expire and shall be null and void.

 

		12.2	Further Assurances. Each of the parties hereto shall perform such further acts and execute
such further documents as may reasonably be necessary to carry out and give full effect to the provisions of this agreement and
the intentions of the parties as reflected thereby.

 

		12.3	Governing Law. This Agreement shall be governed by and construed according to the laws of
the State of Israel, without regard to the conflict of laws provision thereof, and the parties hereto irrevocably submit to the
exclusive jurisdiction of the courts in Tel-Aviv, Israel in respect of any dispute or matter arising out of or connected with this
Agreement.

 

		12.4	Successors and Assigns. Except as otherwise expressly stated to the contrary herein, the
provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns under law, heirs, executors, and
administrators of the parties hereto.

 

		12.5	Entire Agreement; Amendment and Waiver. This Agreement and the Schedules hereto constitute
the full and entire understanding and agreement between the parties with regard to the subject matters hereof and thereof. All
prior understandings and agreements among the Parties are void and of no further effect. Any term of this Agreement may be amended,
waived, or discharged (either prospectively or retroactively, and either generally or in a particular instance), by a written instrument
signed by all the Parties to this Agreement.

 

		12.6	Notices, etc. All notices and other communications required or permitted hereunder to be
given to a party to this Agreement shall be in writing and shall be telecopied or mailed by registered or certified mail, postage
prepaid, or otherwise delivered by hand or by messenger, addressed to such party’s address as set forth in Schedule
‎12.6 attached hereto or at such other address as the party shall have furnished to each other party in writing as
above provided. Any notice sent in accordance with this Section 8.6 shall be effective (i) if mailed by registered or certified
mail, five (5) business days after mailing, (ii) if sent by messenger, upon delivery, and (iii) if send via facsimile, upon transmission
and telephonic confirmation of receipt or (if transmitted and received on a non-business day) on the first business day following
transmission and telephonic confirmation of receipt, or upon receipt of a copy sent by mail as set forth above.

 

    	12

    	 

    

  

		12.7	Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing
to any party upon any breach or default under this Agreement, shall be deemed a waiver of any other breach or default therefore
or thereafter occurring. Any waiver, permit, consent, or approval of any kind or character on the part of any party of any breach
or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must
be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this
Agreement, or by law, or otherwise afforded to any of the parties, shall be cumulative and not alternative.

 

		12.8	Severability. If any provision of this Agreement is held by a court of competent jurisdiction
to be unenforceable under applicable law, then such provision shall be excluded from this Agreement and the remainder of this Agreement
shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms; provided, however,
that in such event this Agreement shall be interpreted so as to give effect, to the greatest extent consistent with and permitted
by applicable law, to the meaning and intention of the excluded provision as determined by such court of competent jurisdiction.

 

		12.9	Counterparts. This Agreement may be executed in any number of counterparts, each of which
shall be deemed an original and enforceable against the parties actually executing such counterpart, and all of which together
shall constitute one and the same instrument.

 

		12.10	Heading, Preamble, and Schedules. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement. The Preamble and Schedules are
an integral and inseparable part of this Agreement.

 

[Remainder of Page Left Intentionally
Blank]

 

    	13

    	 

    

  

IN WITNESS WHEREOF the parties have
signed this Agreement as of the date first hereinabove set forth

 

	Kitov Pharmaceuticals Ltd.	 	Mainrom Line Logistics Ltd.
	 	 	 	 	 
	By:	/s/ Morris Laster	 	By:	/s/ Issac Israel
	 	 	 	 	 
	Name:	Morris Laster, MD	 	Name:	Issac Israel
	 	 	 	 	 
	Title:	President	 	Title:	CEO
	 	 	 	 	 
	SHAREHOLDERS:	 	 	 
	 	 	 	 	 
	/s/ Morris Laster	 	/s/ Haiku Capital Ltd.
	Morris Laster	 	Haiku Capital Ltd.
	 	 	 	 	 
	 	 	 	/s/ Sheer Roichman
	JPW PCH LLC	 	Sheer Roichman
	By:	/s/ J. Paul Waymack	 	 	 
	Name:	J. Paul Waymack	 	 	 
	Title:	CEO	 	 	 

 

    	14

    	 

    

   

SCHEDULE A

 

The registered capital of the Company is
NIS 200,000, divided to 20,000,000 shares in the value of NIS 0.01 per share.

 

List
of shareholders (Outstanding Capital):

 

 

	Shareholders	Total Number of

Shares in the Company	Type of Shares	Value of Each

Share
	Dr Morris Laster	2,000,000	Ordinary	NIS 0.01
	JPW PCH LLC	8,000,000	Ordinary	NIS 0.01
	Total	10,000,000	 	NIS 100,000

 

    	15

    	 

    

  

SCHEDULE ‎1.1

 

Language
for agreement with the Additional Holdings Trustee

 

The parties agree that the Additional Holdings are held pursuant
to this [Trust Agreement] for the sole benefit of Mainrom, and that Mainrom shall have all beneficial rights, ownership or interest
in and to the Additional Holdings and to any of the income, sales proceeds, dividends, distributions, economic or other benefits
resulting from the ownership of the Additional Holdings. It is the intent of the parties that Mainrom shall be deemed to “control”
the Additional Holdings and under all circumstances title to the Additional Holdings shall be distributed to Mainrom at such time
as provided in [the Share Transfer Agreement and this Trust Agreement]

 

    	16

    	 

    

 

SCHEDULE 1.3

 

Milestone

 

The milestone will be met when the pivotal clinical trial has
been completed, the data have been analyzed, and the data analyses have demonstrated that the reduction in blood pressure in the
group treated with the Kitov drug KIT-302 was at least half of that achieved with amlodipine monotherapy.

 

    	17

    	 

    

 

SCHEDULE 1.4

 

Allocation Table in connection with
the Transferred Shares to be transferred by Shareholders to Mainrom & the Issued Shares to be issued by Mainrom to the Shareholders

 

    	18

    	 

    

 

SCHEDULE 1.5A

 

Terms and Conditions of the Options
of Mainrom granted to Simcha Rock at the Closing

 

    	19

    	 

    

 

SCHEDULE 1.5B

Terms and Conditions of the Options
of Mainrom granted to Lior Tamar Investments Ltd. at the Closing

 

	Option Holder(s)	 	Lior Tamar Investments Ltd. ("Lior Tamar"), and/or any other third party as may be designated by Lior Tamar.
	Number of Options	 	Options to purchase 1,194,616 ordinary shares of Mainrom (the "Options").
	Exercise Period	 	Five (5) years as of the date of execution by both parties of an Option Agreement to this effect.
	Exercise Price	 	
        NIS 0.10 per share.

         

	Vesting	 	All Options shall be fully vested and exercisable immediately upon the date of grant of such Options.
	Adjustments	Dividend Distribution:	In the event of dividend distribution during the Exercise Period, the Exercise Price shall be decreased by an amount equal to the dividend amount in NIS. 
	Bonus Shares Issuance:	In the event of a bonus shares issuance during the Exercise Period, the rights of the Option Holder(s) shall be preserved in a manner that immediately after the business day preceding the "ex-dividend" date for the issuance of the bonus shares (in this section the "Determining Date"),  the shares that the Option Holder(s) is entitled to pursuant to the exercise of the Options, shall be increased by an amount equal to the number of the bonus shares such Option Holder(s) would have been entitled to had it exercised its Options immediately prior to the Determining Date allowing it to participate in the issuance of the bonus shares. 
	Offer of securities

 by way of a rights 

issue:	In the event of an offer of securities by way of a rights issue during the Exercise Period, the number of shares the Option Holder(s) is entitled to pursuant to the exercise of Options will be adjusted according to the benefit pursuant to the rights issue, as reflected in the ratio between the price of the share as set on the TASE on the last trading day immediately prior to the "ex" day and the price of the share on the "ex-rights" day.
	Transfer	 	The Options, in whole or in part, may be transferred to any third party designated by the Option Holder(s), provided an appropriate transfer deed is executed by the parties thereto and delivered to the registered office of Mainrom.

 

    	20

    	 

    

 

SCHEDULE 2.3.4

 

Agreement to Terminate JPW PCH LLC's
right to purchase assets from Kitov

 

    	21

    	 

    

 

SCHEDULE 3A

Directors to be appointed to Mainrom's
board of directors at the Closing

 

		1.	Dr. Paul Waymack;

		2.	Dr. Morris Laster; and

		3.	Mr. Simcha Rock

 

    	22

    	 

    

 

SCHEDULE 3B

Directors' Declarations according to
applicable law

 

    	23

    	 

    

 

SCHEDULE 5.1.2

 

Mainrom Share Capital

 
	Shareholders	 	Securities
    
 Allocation	 	 	Securities Type
	Sheer Roichman	 	 	5,418,886	 	 	Ordinary
	Public	 	 	2,186,837	 	 	Ordinary
	Mainrom Line Logistics
    Ltd.	 	 	270	 	 	Ordinary
	Total	 	 	7,605,993	 	 	 

 

    	24

    	 

    

 

SCHEDULE 5.1.5

 

Mainrom's Obligations

 

    	25

    	 

    

 

SCHEDULE 7.1

 

Kitov's Total Obligations and Liabilities

 

    	26

    	 

    

  

SCHEDULE 12.6

 

List of Addresses

 

	Name	 	Address
	Kitov Pharmaceuticals Ltd.	 	
        11 Reuven Shari str., Jerusalem 7246, Israel

         

	Morris Laster	 	
        11 Reuven Shari str., Jerusalem 7246, Israel

         

	
        

        JPW PCH LLC

         
	 	
        1615 Suter's Lane NW,

        Washington DC, 20007, United States

         

	Mainrom Line Logistics Ltd.	 	Capital Point, 132 Menachem Begin str., Tel-Aviv 67021, Israel 
	Sheer Roichman	 	7 Ophir str., Tel-Aviv, Israel
	Haiku Capital Ltd.	 	7 Ophir str., Tel-Aviv, Israel

 

    	27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]